Compounds > ter 286
Page last updated: 2024-09-04

ter 286 and Cancer of Ovary

ter 286 has been researched along with Cancer of Ovary in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brown, G; del Campo, J; Finkler, N; Hunter, J; Jones, M; Kavanagh, J; Kaye, S; Lohr, A; Matei, D; Meng, L; Vergote, I; Vermorken, JB1
Bast, RC; Brown, GL; Jones, MR; Kavanagh, JJ; Levenback, CF; Meng, L; Moore, CL; Ramirez, PT; Wolf, JL1
Boccia, RV; Brown, GL; Burke, JJ; Edwards, RP; Finkler, NJ; Hall, JB; Jones, M; Keck, JG; Melnyk, O; Meng, L; Rankin, EM; Rose, PG; Runowicz, CD; Vergote, I1
Gaté, L; Shen, H; Staros, AL; Tew, KD; Townsend, DM1

Trials

3 trial(s) available for ter 286 and Cancer of Ovary

ArticleYear
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Doxorubicin; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome

2009
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
    Journal of hematology & oncology, 2010, Mar-11, Volume: 3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Survival Analysis; Treatment Failure

2010
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Glutathione; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Survival Analysis; Treatment Outcome; Young Adult

2010

Other Studies

1 other study(ies) available for ter 286 and Cancer of Ovary

ArticleYear
Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:12

    Topics: Antigens, Nuclear; Catalytic Domain; Cell Survival; Chromatography, High Pressure Liquid; Cisplatin; Cytotoxins; Dimerization; DNA Helicases; DNA-Activated Protein Kinase; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Female; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Immunoblotting; Inhibitory Concentration 50; Isoenzymes; Ku Autoantigen; Models, Chemical; Nuclear Proteins; Ovarian Neoplasms; Precipitin Tests; Prodrugs; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tumor Cells, Cultured

2002